MP49-07 EFFICACY AND SAFETY OF RENAL CRYOABLATION IN THE TREATMENT OF RENAL CELL CARCINOMA: A MULTI-CENTER PROSPECTIVE REGISTRY STUDY

Abstract

Listen

Translate article

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy IV (MP49)1 Sep 2021MP49-07 EFFICACY AND SAFETY OF RENAL CRYOABLATION IN THE TREATMENT OF RENAL CELL CARCINOMA: A MULTI-CENTER PROSPECTIVE REGISTRY STUDY Stephen J. Savage, Peter E. Clark, and S. Duke Herrell Stephen J. SavageStephen J. Savage More articles by this author , Peter E. ClarkPeter E. Clark More articles by this author , and S. Duke HerrellS. Duke Herrell More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002075.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Management of small renal cell carcinoma (RCC), specifically clinical T1a RCC, includes a variety of treatment options. However, many of the studies supporting these options are retrospective reviews of a single institution—or even single provider—and thus suffer from concerns about the reproducibility of the results across sites. We present the interim analysis results of a rigorous, high-quality prospective registry collecting comprehensive data from multiple institutions and experts on the efficacy of cryoablation for the treatment of renal lesions. METHODS: TRACE (Tracking Renal Tumors After Cryoablation Evaluation) is a multicenter, prospective, observational, open-label, registry study of patients with an enhancing renal mass suspicious for malignancy. Patients were treated with cryoablation and subsequently followed for five years. RESULTS: Over a 6-year period, seven centers enrolled and treated 250 patients with cryoablation. 246 patients with 252 lesions met inclusion criteria. Of those, 145/246 (58.9%) patients with 146 lesions have biopsy-proven RCC. At the time of this interim analysis, the median follow-up was 42.4 months (0.03-78.29). Overall median lesion size was 2.5 cm. Cryoablation was completed in 245/246 (99%) cases, with 99 procedures performed laparoscopically, 146 percutaneously, and one with an open procedure. There were 42 treatment-related adverse events and 11 serious adverse events totaling 53 adverse events in 40/246 (16.3%) patients. Of these adverse events, 11.3% (6/53) were Clavien-Dindo class III, with no class IV or V events. Only minimal change in renal function was noted in the 12-month period post treatment. The median estimated glomerular filtration rate decreased 3.85 mL/min with a median increase in creatinine of 0.06 mg/dL. The 36-month Kaplan-Meier estimate of time to recurrence, disease specific survival and overall survival for the RCC population was 94.8%, 100% and 91.9%, respectively. CONCLUSIONS: This rigorous, multicenter prospective study provides high-quality, reproducible evidence supporting the efficacy of cryoablation as a primary treatment for clinically suspicious renal masses. Source of Funding: This study was sponsored by BTG International/Boston Scientific Corporation © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e877-e878 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Stephen J. Savage More articles by this author Peter E. Clark More articles by this author S. Duke Herrell More articles by this author Expand All Advertisement Loading ...